368 related articles for article (PubMed ID: 36980956)
21. High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers.
González-Acosta M; Marín F; Puliafito B; Bonifaci N; Fernández A; Navarro M; Salvador H; Balaguer F; Iglesias S; Velasco A; Grau Garces E; Moreno V; Gonzalez-Granado LI; Guerra-García P; Ayala R; Florkin B; Kratz C; Ripperger T; Rosenbaum T; Januszkiewicz-Lewandowska D; Azizi AA; Ragab I; Nathrath M; Pander HJ; Lobitz S; Suerink M; Dahan K; Imschweiler T; Demirsoy U; Brunet J; Lázaro C; Rueda D; Wimmer K; Capellá G; Pineda M
J Med Genet; 2020 Apr; 57(4):269-273. PubMed ID: 31494577
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
23. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
[TBL] [Abstract][Full Text] [Related]
24. The genetics of hereditary colon cancer.
Rustgi AK
Genes Dev; 2007 Oct; 21(20):2525-38. PubMed ID: 17938238
[TBL] [Abstract][Full Text] [Related]
25. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Sorscher S; Ramkissoon S
Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
[TBL] [Abstract][Full Text] [Related]
26. When and how to perform genetic testing for inherited colorectal cancer syndromes.
Lynch PM
J Natl Compr Canc Netw; 2013 Dec; 11(12):1577-83. PubMed ID: 24335689
[TBL] [Abstract][Full Text] [Related]
27. Lynch or not Lynch? Is that always a question?
Colas C; Coulet F; Svrcek M; Collura A; Fléjou JF; Duval A; Hamelin R
Adv Cancer Res; 2012; 113():121-66. PubMed ID: 22429854
[TBL] [Abstract][Full Text] [Related]
28. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series.
Kidambi TD; Pedley C; Blanco A; Bergsland EK; Terdiman JP
Fam Cancer; 2017 Oct; 16(4):537-543. PubMed ID: 28283864
[TBL] [Abstract][Full Text] [Related]
29. Hereditary gynecologic tumors and precision cancer medicine.
Ogawa C; Hirasawa A; Ida N; Nakamura K; Masuyama H
J Obstet Gynaecol Res; 2022 May; 48(5):1076-1090. PubMed ID: 35229413
[TBL] [Abstract][Full Text] [Related]
30. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study.
Rütten A; Burgdorf W; Hügel H; Kutzner H; Hosseiny-Malayeri HR; Friedl W; Propping P; Kruse R
Am J Dermatopathol; 1999 Oct; 21(5):405-13. PubMed ID: 10535567
[TBL] [Abstract][Full Text] [Related]
31. Germline variants screening of MLH1, MSH2, MSH6 and PMS2 genes in 64 Algerian Lynch syndrome families: The first nationwide study.
Boumehdi AL; Cherbal F; Khider F; Oukkal M; Mahfouf H; Zebboudj F; Maaoui M
Ann Hum Genet; 2022 Nov; 86(6):328-352. PubMed ID: 36073783
[TBL] [Abstract][Full Text] [Related]
32. Clinical genetics of hereditary colorectal cancer.
Power DG; Gloglowski E; Lipkin SM
Hematol Oncol Clin North Am; 2010 Oct; 24(5):837-59. PubMed ID: 20816577
[TBL] [Abstract][Full Text] [Related]
33. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.
Agarwal R; Liebe S; Turski ML; Vidwans SJ; Janku F; Garrido-Laguna I; Munoz J; Schwab R; Rodon J; Kurzrock R; Subbiah V;
Discov Med; 2014 Dec; 18(101):331-9. PubMed ID: 25549704
[TBL] [Abstract][Full Text] [Related]
35. Increased Risk of Hereditary Prostate Cancer in Italian Families with Hereditary Breast and Ovarian Cancer Syndrome Harboring Mutations in
D'Elia G; Caliendo G; Tzioni MM; Albanese L; Passariello L; Molinari AM; Vietri MT
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292577
[TBL] [Abstract][Full Text] [Related]
36. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
37. Management of Colorectal Cancer in Hereditary Syndromes.
Cunningham LA; Gasior A; Kalady MF
Surg Oncol Clin N Am; 2022 Apr; 31(2):307-319. PubMed ID: 35351280
[TBL] [Abstract][Full Text] [Related]
38. [Specific features of drug sensitivity of hereditary cancers].
Imyanitov EN
Vopr Onkol; 2016; 62(2):221-6. PubMed ID: 30452211
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
[TBL] [Abstract][Full Text] [Related]
40. Two Cases of Carcinosarcomas of the Ovary Involved in Hereditary Cancer Syndromes.
Carnevali IW; Cimetti L; Sahnane N; Libera L; Cavallero A; Formenti G; Riva C; Tibiletti MG
Int J Gynecol Pathol; 2017 Jan; 36(1):64-70. PubMed ID: 27167672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
